Therapeutic validation and targeting of signalling networks that are dysregulated in intellectual disability

FEBS J. 2023 Mar;290(6):1454-1460. doi: 10.1111/febs.16411. Epub 2022 Feb 28.

Abstract

Intellectual disability (ID) represents a major burden on healthcare systems in the developed world. However, there is a disconnect between our knowledge of genes that are mutated in ID and our understanding of the underpinning molecular mechanisms that cause these disorders. We argue that elucidating the signalling and transcriptional networks that are dysregulated in patients will afford new therapeutic opportunities.

Keywords: intellectual disability; neurodevelopmental disorders; post-translational modification; signal transduction; stem cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Intellectual Disability* / genetics
  • Signal Transduction